Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 + Oxaliplatin in Locally Advanced Rectal Cancer
NCT07090031Phase 2Active, not recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in rectal cancer, sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoints: Pathological Complete Response at 24 months and Pathological Complete Response Rate at 24 months. Started Jul 2025; status: active, not recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07090031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090031.